Assessment of in vivo anti-tumor activity of human umbilical vein endothelial cell vaccines prepared by various antigen forms

Zhou, Ling; Si, Chunfeng; Li, Defang; Lu, Meiyu; Zhong, Weilan; Xie, Zeping; Guo, Lin; Zhang, Shumin; Xu, Maolei

doi:10.1016/j.ejps.2017.12.020

Cited by 7 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HUVECs have been proved as an effective whole-cell vaccine inhibiting tumor angiogenesis. 13 , 19 However, Primary cultured HUVECs divide a very limited number of passages before entering replicative senescence, and the cost of cell culture is high, which limit its application for clinical situation.…”

Section: Discussionmentioning

confidence: 99%

制备人脐静脉内皮细胞和人肺腺癌细胞融合细胞的新方法

席

2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

Purpose: Human umbilical endothelial cells (HUVECs) have been proved to be an effective whole-cell vaccine inhibiting tumor angiogenesis. In this study, we fused HUVECs with human lung adenocarcinoma cells A549 s, aiming at preparing lung cancer vaccine to achieve dual effects of anti-tumor angiogenesis and specific immunity to tumor cells. Methods: A549 cells were induced by ethyl methane sulfonate (EMS) and 8-azaguanine (8-AG) to get hypoxanthine guanine phosphoribosyl transferase (HGPRT) auxotrophic A549 cells. Then Fused HGPRT auxotrophic A549 cells with primary HUVEC cells by combining electrofusion with polyethylene glycol (PEG). Afterward the fusion cells were screened by HAT and HT selective medium and sorted by flow cell sorter to obtain high-purity HUVEC-A549 cells. Finally, HUVEC-A549 cells were identified by karyotype analysis and western blotting. Results: The fusion efficiency of HUVEC-A549 cells prepared by combining electrofusion with polyethylene glycol (PEG) was significantly higher than that of electrofusion and PEG (43.0% vs 17.60% vs 2.71%, P < 0.05). After screened by HAT and HT selective medium and sorted by flow cell sorter, the proportion of HUVEC-A549 cells can count for 71.2% ± 3.2%. The mode of chromosomes in HUVEC-A549 cells was 68, and the chromosome was triploid. VE-cadherin and platelet endothelial cell adhesion molecule-1 (CD31) were highly expressed in HUVECs and HUVEC-A549 cells, but not in A549 cells. Conclusions: These results indicate that HUVEC-A549 cells retain the biological characteristics of human umbilical vein endothelial cells and A549 cells. It can be used in the experimental study of lung cancer cell vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

制备人脐静脉内皮细胞和人肺腺癌细胞融合细胞的新方法

席

2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Fixed xenogeneic endothelial cells have been applied as a vaccine in the immunotherapy of tumors such as lung cancer, hepatoma, and colorectal carcinoma [8,12,30]. To inspect the antitumor effect of HUVECs induced by TCM, we adopted the murine colorectal carcinoma animal model.…”

Section: Resultsmentioning

confidence: 99%

“…The positive bands were therefore presumed to be TEM1, VEGFR2, and TEM8 (Figure 3E). The testing method of anti-HUVEC antibody level induced by HUVEC vaccine and related vaccines has been reported previously [8,12,31]. In this study, the level of anti-induced HUVEC membrane protein antibody was examined by an ELISA assay.…”

Section: Resultsmentioning

confidence: 99%

“…Due to the importance of tumor angiogenesis in the progression of solid tumors, vaccines with xenogeneic or syngeneic endothelial cells targeting tumor angiogenesis have been proven effective [8,10,34]. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine can break the body’s immune tolerance to its own vascular endothelial cells, induce the immune response against its own tumor vessels, destroy the neovascularization, and inhibit the growth of tumors [7,35].…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies have demonstrated that a human umbilical vein endothelial cell (HUVEC) vaccine could inhibit tumors by initiating antiangiogenic effects with both cellular and humoral immunity [7,8,9,10]. Presenting various growth factors during angiogenesis, endothelial cell vaccines may be more effective than targeting one specific antigen in tumor blood vessels.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Improved Antitumor Efficacy of Combined Vaccine Based on the Induced HUVECs and DC-CT26 Against Colorectal Carcinoma

Zhang

Xie

Wang

et al. 2019

Cells

View full text Add to dashboard Cite

Angiogenesis is essential for the development, growth, and metastasis of solid tumors. Vaccination with viable human umbilical vein endothelial cells (HUVECs) has been used for antitumor angiogenesis. However, the limited immune response induced by HUVECs hinders their clinical application. In the present study, we found that HUVECs induced by a tumor microenvironment using the supernatant of murine CT26 colorectal cancer cells exerted a better antiangiogenic effect than HUVECs themselves. The inhibitory effect on tumor growth in the induced HUVEC group was significantly better than that of the HUVEC group, and the induced HUVEC group showed a strong inhibition in CD31-positive microvessel density in the tumor tissues. Moreover, the level of anti-induced HUVEC membrane protein antibody in mouse serum was profoundly higher in the induced HUVEC group than in the HUVEC group. Based on this, the antitumor effect of a vaccine with a combination of induced HUVECs and dendritic cell-loading CT26 antigen (DC-CT26) was evaluated. Notably, the microvessel density of tumor specimens was significantly lower in the combined vaccine group than in the control groups. Furthermore, the spleen index, the killing effect of cytotoxic T lymphocytes (CTLs), and the concentration of interferon-γ in the serum were enhanced in the combined vaccine group. Based on these results, the combined vaccine targeting both tumor angiogenesis and tumor cells may be an attractive and effective cancer immunotherapy strategy.

show abstract

New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis

Zhou

Xue

et al. 2023

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Assessment of in vivo anti-tumor activity of human umbilical vein endothelial cell vaccines prepared by various antigen forms

Cited by 7 publications

References 28 publications

制备人脐静脉内皮细胞和人肺腺癌细胞融合细胞的新方法

制备人脐静脉内皮细胞和人肺腺癌细胞融合细胞的新方法

Improved Antitumor Efficacy of Combined Vaccine Based on the Induced HUVECs and DC-CT26 Against Colorectal Carcinoma

New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis

Contact Info

Product

Resources

About